Conferences

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to a genitourinary cancers poster session. Dr. Vincent Habouzit presented the results of a nationwide study evaluating factors associated with clinical and biologic responses in French patients receiving [¹⁷⁷Lu]Lu-PSMA-617 under France’s early access program.

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 16^th, 2024 was host to a genitourinary cancers poster session. Dr. Evan Yu presented the results of ARROW, a multicenter randomized phase II trial of PSMA-targeted radioligand therapy with ¹³¹I-LNTH-1095 plus enzalutamide versus enzalutamide alone in chemotherapy-naïve metastatic castrate-resistant prostate cancer (mCRPC) patients with disease progression on abiraterone and positive piflufolastat F 18 scans.

(UroToday.com) The 2024 ESMO annual meeting included a session on urothelial carcinoma, featuring a presentation by Dr. Joshua Meeks discussing a prospective evaluation of BCG unresponsive bladder cancer carcinoma in situ (CIS) to identify genetic mechanisms of immunotherapy resistance and targeted therapy using an ultra-sensitive next-generation sequencing minimal residual disease assay.

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to a genitourinary cancers poster session. Dr. Martina Buffoni presented the results of the BonEnza trial that evaluated total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation therapy (ADT) and enzalutamide +/- zoledronic acid.

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to a genitourinary cancers poster session. Dr. Lisa Horvath presented the results of an ad hoc analysis of the ENZAMET trial (ANZUP 1304) evaluating the association between the lipid biomarker, PCPro, and clinical outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) patients.

(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Kambiz Rahbar discussing the final safety and efficacy analysis of RaLu assessing ¹⁷⁷Lu-PSMA therapy in patients with prior radium‑223. Radium-223 is an established alpha particle emitting radionuclide therapy with an acceptable safety profile. It prolongs overall survival and improves quality of life in patients with bone predominant metastatic castration-resistant prostate cancer (mCRPC).¹ PSMA-targeted radioligand therapies have demonstrated anticancer activity [2]. More recently, ¹⁷⁷Lu-PSMA was shown to have an acceptable safety profile and to extend overall survival in heavily pre-treated PSMA-positive patients with mCRPC, including taxane based chemotherapy and radium-223. The safety and efficacy of sequential use of radium‑223 and ¹⁷⁷Lu-PSMA in patients with mCRPC were assessed in the real-world RaLu study [3] conducted across multiple centers in Germany and Israel.

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to a genitourinary cancers poster session. Dr. Jwa Hoon Kim presented the initial results of RENOIR (KCSG GU22-13), a real-world study of 1^st line nivolumab plus ipilimumab in advanced renal cell carcinoma (RCC) patients.

(UroToday.com) The 2024 ESMO annual meeting included a session on addressing uncertainties in the management of urothelial and renal cell carcinomas, featuring a presentation by Dr. Debbie Robbrecht discussing how to manage patients with durable response on systemic therapy and whether there is a role in de-escalation. Dr. Robbrecht started by highlighting 8 patient scenarios from her clinical practice whereby patients may have been candidates for de-escalation of therapy:

(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Michael Hofman discussing Prostate Cancer Working Group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation. The PCWG3 consensus guidelines have proven a robust set of imaging endpoints incorporated into most prostate cancer trials. ⁶⁸Ga-PSMA-11, ¹⁸F-DCFPyL, and ¹⁸F-rhPSMA-7.3 PET/CT are all FDA approved, and recommended for staging and biochemical recurrence. Further, the randomized ProPSMA study demonstrated accuracy exceeding CT and bone scintigraphy.¹ An expert committee of clinical investigators (PCWG4) met in 2023 to consider preliminary imaging criteria that incorporated PSMA PET/CT response assessments. Proposed criteria described complete and partial response, stable disease, and progressive disease. Dr. Hofman and colleagues sought to determine reader reproducibility and the clinical correlation of these categories using a trial dataset that incorporated 12-weekly PSMA PET/CT alongside standard CT / bone scan (PCWG3) assessments.

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between was host to a genitourinary cancers poster session. Professor Laurence Albiges presented the final results of CaboPoint, a phase II trial of cabozantinib after checkpoint inhibitor combinations in patients with advanced renal cell carcinoma (RCC).

(UroToday.com) The 2024 ESMO annual meeting included a session on addressing uncertainties in the management of urothelial and renal cell carcinomas, featuring a presentation by Dr. Begona Perez-Valderrama discussing how to build on standard therapies by assessing novel agents and promising combinations. Since 2010, there have been numerous FDA and EMA approvals of new agents in renal cell carcinoma, prostate cancer, and urothelial carcinoma:

(UroToday.com) The 2024 ESMO annual meeting included a session on addressing uncertainties in the management of urothelial and renal cell carcinomas, featuring a presentation by Dr. Bernadett E. Szabados discussing circulating versus tissue-based biomarkers.

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to a genitourinary cancers poster session. Professor Karim Fizazi presented updated results of the phase II CYPIDES trial of opevesostat (ODM-208/MK-5684), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC) patients.

(UroToday.com)  The 2024 ESMO annual meeting included a session on addressing uncertainties in the management of urothelial and renal cell carcinomas, featuring a presentation by Dr. Yohann Loriot discussing the role of rechallenge with the same class of agents in advanced disease. Dr. Loriot notes that this is an old question revisited with the coming of new drugs. When discussing re-treatment and re-challenge, it is important to define these scenarios. These include a fixed duration of treatment (ie. adjuvant therapy), a toxicity event, or progressive disease:

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13^th and 16^th, 2024 was host to a genitourinary cancers poster session. Dr. Yohann Loriot presented SOGUG-NEOWIN, an ongoing open label, multicenter phase II trial evaluating the efficacy and safety of both erdafitinib monotherapy and combination erdafitinib and cetrelimab as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) and Fibroblast Growth Factor Receptor (FGFR3) gene alterations.

(UroToday.com) The 2024 ESMO annual meeting included a session on expanding bladder preservation by optimal use of systemic therapy and biomarkers, featuring a presentation by Dr. James Catto discussing the role of the urologist in bladder preservation strategies.

• Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC
• Phase 2 dose expansion currently underway at the RP2CDs of masofaniten 600 mg BID in combination with enzalutamide 160 mg QD
• Across all dosing cohorts, 88% of patients achieved PSA90, 69% of patients achieved PSA90 in less than 90 days, and 63% of patients achieved PSA <0.2ng/mL. After 15.2 months of follow up, median time to PSA progression and radiographic progression free survival have not yet been reached.

(UroToday.com) The 2024 ESMO annual meeting included a session on expanding bladder preservation by optimal use of systemic therapy and biomarkers, featuring a presentation by Dr. Leslie Ballas discussing whether clinical responders have an option for chemoradiation. Dr. Ballas started by highlighting that based on the SWOG 8710 trial of neoadjuvant chemotherapy + cystectomy,¹ we know that achieving a pT0 response leads to increased survival. Patients that received neoadjuvant chemotherapy had a pT0 rate of 38% versus 15% for pT0 among patients without neoadjuvant chemotherapy.

(UroToday.com) The 2024 ESMO annual meeting included a session on expanding bladder preservation by optimal use of systemic therapy and biomarkers, featuring a presentation by Dr. Eva Schaake discussing biomarkers and prediction of clinical complete response. The prognosis of stage II-III urothelial cancer is poor, with a 5-year overall survival of only 25-47% after radical cystectomy. Cisplatin-based neoadjuvant chemotherapy can modestly improve overall survival, but there is no biomarker for response in clinical practice. Immunotherapy combination trials show encouraging activity and may have less cross resistance with chemo-radiotherapy. Currently, there are better bladder sparing options emerging with increasing efficacy of new treatment combinations and improved trimodality treatment. As such, biomarkers could help select candidates for bladder-sparing options, especially in high-risk disease.